ABSTRACT
Background Whether the use of fludrocortisone affects outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH) and its usage rate in the United States remain unknown.
Methods We conducted a retrospective analysis of 78 consecutive patients with a ruptured aSAH at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. We adjusted the primary outcome for age, hypertension, aSAH grade, and time from aSAH onset to aneurysm treatment. Secondary outcomes were brain and cardiopulmonary dysfunction events.
Results Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5]; 64% were female, and 41 (53%) received fludrocortisone. The adjusted common odds ratio, aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95% CI, 0.14-0.80; P=0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction events were not statistically different: delayed cerebral ischemia (22% vs. 39%, P=0.16); cardiac dysfunction (0% vs. 11%; P=0.10); and pulmonary edema (15% vs. 8%; P=0.59).
Conclusions The risk of disability or death at 90 days was lower with the use of fludrocortisone in aSAH patients.
Competing Interest Statement
Isaac Abecassis has the following disclosures: 1) Remedy Robotics: Consultant, Equity. 2) IschemaView Inc/Rapid AI: Clinical consultant. 3) Rapid Medical: Consultant. 4) Balt: Consultant. 5) CNS Foundation: Grant Research Support.
Funding Statement
This study was funded by the Vanderbilt Institute for Clinical and Translational Research (UL1TR000445 and UL1TR002243 from NCATS/NIH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Vanderbilt University Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: was provided by the Vanderbilt Institute for Clinical and Translational Research (UL1TR000445 and UL1TR002243 from NCATS/NIH).
Disclosures: Isaac Abecassis has the following disclosures: 1) Remedy Robotics: Consultant, Equity. 2) IschemaView Inc/Rapid AI: Clinical consultant. 3) Rapid Medical: Consultant. 4) Balt: Consultant. 5) CNS Foundation: Grant Research Support.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
